Know Cancer

forgot password

A Phase I Study to Evaluate the Safety and Pharmacokinetics of S-CKD602 in Patients With Advanced Malignancies

Phase 1
18 Years
Not Enrolling

Thank you

Trial Information

A Phase I Study to Evaluate the Safety and Pharmacokinetics of S-CKD602 in Patients With Advanced Malignancies

The main purposes of this study are:

To determine the maximum tolerated dose (highest dose that can safely be given to subjects)
of S CKD602 when given every three weeks.

To determine the incidence and severity of toxicity (side-effects) of S CKD602 when given
every three weeks.

To determine a subject's body handles the drug (pharmacokinetics) following administration
of S CKD602.

In addition to the above, we would also like to analyze how the genes (material inside each
cell that is responsible for cell functioning and appearance) found in a subject's blood
affect how the study drug S-CKD602 is broken down in a subject's body. This process is
referred to as “metabolic genotyping analyses”. This evaluation is performed using a blood
sample and is optional.

Inclusion Criteria:

Male or female subjects with an age > 18 years Histologically or cytologically proven
malignancy, unresponsive to curative surgery, radiotherapy, conventional chemotherapy or
for which no conventional therapy exists. (Measurable or evaluable disease is desirable,
but not required) Note: This study is restricted to patients with advanced solid tumors,
subjects with hematological malignancies are excluded (including lymphoma and leukemia)
ECOG Performance Status 0- 2 Adequate bone marrow function, without the support of
cytokines and/or Epoetin Alpha within 5 days prior to dosing: Absolute neutrophil count
(ANC) >1,500/mm3, platelet count > 100,000/mm3, Hgb > 9.0 g/dL. Adequate liver function:
total bilirubin level < 2.0 mg/dL, ALT and AST < 2.0 x institutional upper limit of
normal in the absence of liver metastasis, or < 4.0 x institutional upper limit of normal
in the presence of liver metastasis.

Adequate renal function: serum creatinine < 1.5 mg/dL. At least 3 weeks since prior
chemotherapy or cancer surgery (6 weeks for nitrosourea or mitomycin C).

Normal cardiac function with no history of uncontrolled heart disease. Women subjects (if
of child bearing potential and sexually active) and male subjects (if sexually active with
a partner of child bearing potential) must use medically acceptable methods of birth
control prior to study entry and for the duration of the study. Medically acceptable
methods of contraception that may be used by the subject and/or his/her partner include
abstinence, birth control pills or patches, diaphragm and spermicide, IUD, condom and
vaginal spermicide, surgical sterilization, post menopausal, vasectomy, and progestin
implant or injection.

Written informed consent.

Exclusion Criteria:

Subject is pregnant or is breast feeding. Subject's life expectancy is less than 3 months.
Subject exhibits confusion, disorientation, or has a history of major Psychiatric illness,
which may potentially impair subject's understanding of the informed consent.

Subject has signs and symptoms of acute infection requiring systemic therapy. Subject has
used another investigational agent within 30 days of dosing with S CKD602.

Subjects with known allergic reactions to camptothecin analogs, dextran sulfate or other
components of S-CKD602 Symptomatic or uncontrolled brain leptomeningeal metastasis. CT
scans are not required unless there is clinical suspicion of central nervous disease.

Not recovered from reversible toxicity of prior therapy. Subjects with known brain
metastases because of their poor prognosis because they often develop progressive
neurologic dysfunction that would confound the evaluation of neurologic and other adverse

Concurrent radiation therapy or radiation within 3 weeks of starting treatment with

Concurrent anti-neoplastic agents.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose of S CKD602 when given every three weeks.

Principal Investigator

Ramesh K Ramanathan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh


United States: Food and Drug Administration

Study ID:




Start Date:

September 2003

Completion Date:

April 2008

Related Keywords:

  • Cancer



University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213